Financial Press Releases

Holding(s) in Company
Holding(s) in Company
April 1, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 31 March 2021.

Investor Presentation
Investor Presentation
April 1, 2021

Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST.

Final results for the year ended 31 December 2020
Final results for the year ended 31 December 2020
April 1, 2021

The Company is pleased to announce its audited results for the year ended 31 December 2020.

Loan amendment
Loan amendment
March 30, 2021

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited (“VIM”) (the “Loan”).  The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2022 (previously 1 May 2021) (the “Loan Amendment”).  All other terms of the Loan remain the same as announced on 3 July 2018, including that interest will accrue at the annual rate of 2.5 per cent. above the UK sterling base rate of Barclays Bank plc.

Holdings in Company
Holdings in Company
March 29, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 29 March 2021.

Trading Update and Notice of Results
Trading Update and Notice of Results
March 26, 2021

Following the Company’s announcement on 25 January 2021 the Company has been progressing the year end audit and anticipates being able to announce the 2020 full year results on Thursday, 1 April 2021. The Directors of Proteome Sciences are pleased to announce that the Company now expects to report profit after tax materially higher than announced on 25 January.  This is primarily due to higher than expected royalty receipts from Thermo Scientific for the last quarter of 2020.  The annual results are still subject to finalisation of the audit and approval by the Board.

Year End Trading Update
Year End Trading Update
January 25, 2021

The Company today provides a trading update for the financial year ended 31 December 2020.

Holding(s) in Company
Holding(s) in Company
January 18, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 15 January 2021.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 15, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 14 September 2020 it purchased 363,037 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.96p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,826,194 Ordinary Shares, equivalent to 22.30% of Proteome Sciences' total issued share capital.

Appointment of Chief Executive Officer
Appointment of Chief Executive Officer
September 14, 2020

The Board of Proteome Sciences plc is pleased to announce that Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020. Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen’s appointment.